MedTrace Logo

Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis.

NCT04792138 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-03-10

No results posted yet for this study

Summary

Multiparametric magnetic resonance imaging (mpMRI) is now widely used to risk stratify men with a suspicion of prostate cancer and identify suspicious regions for biopsy. Advanced MRI techniques have emerged which seek to improve this characterisation and could predict biopsy results non-invasively before men undergo biopsy. Before these techniques are translated clinically, robust histological and clinical validation is required.

This study aims to clinically validate advanced MRI techniques in a cohort of men suspected with prostate cancer. Histological analysis of men undergoing biopsy, +/- prostatectomy will be used for biological validation of VERDICT; Vascular and Extracellular Restricted Diffusion for Cytometry in Tumours and Luminal Water imaging (LWI). In particular, prostatectomy specimens will be processed using 3-D printed patient-specific moulds to allow for accurate MRI and histology mapping.

Conditions

Interventions

DIAGNOSTIC_TEST

VERDICT MRI

Advanced Diffusion Model

DIAGNOSTIC_TEST

Luminal Index Imaging

Advanced T2 mapping

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Shonit Punwani · University College, London

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-23
Primary Completion
2022-10-31
Completion
2023-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04792138 on ClinicalTrials.gov